Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

FDA Approves Extended-Release Amantadine (GOCOVRI™) for Treatment of Dyskinesia

Statement from the Parkinson's Foundation Medical Director, Michael Okun, MD

"Today, Adamas announces FDA approval of an extended release amantadine capsule called GOCOVRI. This drug will provide a practical once a day solution for dyskinesia management and reducing "off" time. Patients who are currently well managed using multiple doses per day of generic amantadine for dyskinesia will not likely derive additional symptomatic benefits from switching to once a day dosing; however, patients experiencing side effects from amantadine may wish to discuss options with their neurologist.

Both GOCOVRI and generic amantadine use is linked to a risk of side effects such as dizziness, hallucinations or blotching on the skin of the legs.  If you are considering starting this medicine or switching to this medicine we recommend consulting with your doctor.

In an independent Parkinson's Foundation study prior to this approval, we found that generic amantadine use improved dyskinesia in patients.  However, amantadine use does have a risk of side effects including insomnia and hallucinations. GOCORVI has been designed to limit the risk of these complications and it will not carry generic amantadine's warning for insomnia."

Call our Helpline, 1-800-4PD-INFO, or visit www.GOCOVRI.com for more information.

About the Parkinson's Foundation

The Parkinson's Foundation is working toward a world without Parkinson's disease. Formed by the merger of National Parkinson Foundation (NPF) and the Parkinson's Disease Foundation (PDF), the mission of the Parkinson's Foundation is to invest in promising scientific research that will end Parkinson's disease and improve the lives of people with Parkinson's, and their families, through improved treatments, support and the best care. For more information, visit www.parkinson.org, or call (800) 4PD-INFO (473-4636).

About Parkinson's Disease (PD)

Affecting an estimated one million Americans and 10 million worldwide, PD is the second-most common neurodegenerative disease after Alzheimer's and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression) as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for PD and 60,000 new cases are diagnosed each year in the United States alone.

# # #

Friday, August 25, 2017
PDF Research Advocates Guide $16 Million in Parkinson’s Research Funding
Wednesday, June 15, 2016

Recently, two Parkinson’s Disease Foundation (PDF) volunteers helped guide $16 million in government funding for Parkinson’s disease (PD) research.

This spring, Sam Erwin, M.S., M.A., of West Des Moines, IA, and Paul Zimmet, D.D.S., of Reston, VA – both PDF Research Advocates, people living with PD and US Army Veterans – served as consumer reviewers of research funded by the US Department of Defense (DoD).

Parkinson's Disease Foundation Announces $4 Million in Research Investments to Solve, Treat and End Parkinson's Disease
Thursday, June 9, 2016

Research Funding for Early-Career Scientists Reflects Urgent Need for Better Therapies

Adaptive Athlete Announces 300 Skydives in 24 Hours
Wednesday, June 8, 2016

“300 Imperfect Jumps” Raises Funds for Parkinson’s Disease Research

NPF Celebrates the Life and the Legend of Muhammad Ali
Saturday, June 4, 2016

MIAMI — Today we mourn the loss and celebrate the life of Muhammad Ali, a longtime friend of the National Parkinson Foundation (NPF). Mr. Ali passed away at age 74 after being hospitalized for respiratory problems, a common complication in advanced Parkinson’s disease.

Parkinson’s Disease Foundation Marks Tenth Year of People with Parkinson’s Advisory Council
Tuesday, May 24, 2016

Patient Advisors Drive PDF Mission to Solve, Treat and End Parkinson’s

The Parkinson’s Disease Foundation® (PDF®) is pleased to mark the tenth year of its People with Parkinson’s Advisory Council and welcome five new members. Created in 2006, the council is made up of people living with Parkinson’s and care partners who drive PDF’s goals of ending the disease and improving the lives of those affected by it.

Fourth Annual Celebrate Spring Boston Raises $50,000 for Parkinson’s Disease Foundation
Tuesday, May 3, 2016

Boston Area Women Inspire Fellow Young Professionals to End Parkinson’s

FDA Approves Drug to Treat Parkinson’s Disease Psychosis
Friday, April 29, 2016

Today, the FDA approved Nuplazid (pimavanserin) as the first drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis, which affects up to 40% of people with Parkinson’s.

FDA Panel Backs Approval of Pimavanserin
Tuesday, March 29, 2016

Big News for Advanced Parkinson’s

Lea Dempsey, Seventh Grader from NJ, Designs Winning Parkinson’s Awareness T-Shirt
Thursday, March 24, 2016

A digital drawing by 13-year-old Lea Dempsey of Princeton, NJ, came out on top in the Parkinson’s Disease Foundation’s (PDF) Seventh Annual Parkinson’s Awareness T-Shirt Design Contest. In PDF’s “kids only” contest, Ms. Dempsey’s design was a contender along with 20 other submissions from children ages five to 15-years-old. Her design was chosen as the winner by the general public in an online vote.

National Parkinson Foundation Campaign Promotes the Power of Exercise During Parkinson’s Disease Awareness Month
Monday, March 21, 2016

The National Parkinson Foundation (NPF) launched the #Move4PD campaign in recognition of National Parkinson’s Disease Awareness Month today. The campaign’s goal is to highlight the importance of exercise for those with Parkinson’s disease (PD) and its positive effects on the brain.

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.